EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Drug therapy for myocarditis induced by immune checkpoint inhibitors

Yihao Wu, Yizhou Xu, Linhao Xu

Frontiers in Pharmacology · 25.05.2023 · 14

DOI: 10.3389/fphar.2023.1161243 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Frontiers in Pharmacology, online erschienen am 25.05.2023. Verfasst von Yihao Wu und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Affiliated Hangzhou First People's Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 111 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Immune checkpoint inhibitors (ICIs), including cytotoxic T-lymphocyte antigen 4 (CTLA-4), programmed cell death 1 (PD-1), and its ligand 1 (PD-L1), have improved the survival in multiple types of cancers; however, ICIs may cause cardiovascular toxicity. Although rare, ICI-mediated cardiotoxicity is an extremely serious complication with a relatively high mortality. In this review, we discuss the underlying mechanism and clinical manifestations of cardiovascular toxicity induced by ICIs. According to previous studies, multiple signaling pathways are involved in myocarditis induced by ICIs. Further, we summarize the clinical trials of drugs for the treatment of ICI-associated myocarditis. Although these drugs have shown the beneficial effects of alleviating cardiac function and reducing mortality rates, their efficacy is not optimal. Finally, we discuss the therapeutic potential of some novel compounds as well as the underlying mechanisms of their action.

Schlagwörter

Stichwörter der Autor:innen

cardiotoxicitycytotoxic T-lymphocyte antigen 4fibrosisimmune checkpoint inhibitorsinflammationmyocarditisprogrammed cell death 1

Autor:innen und Institutionen

  • Department of Cardiology, Affiliated Hangzhou First People's Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.
  • Department of Laboratory Medicine, Affiliated Hangzhou First People's Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.

Zitieren

APA

Wu, Y., Xu, Y., & Xu, L. (2023). Drug therapy for myocarditis induced by immune checkpoint inhibitors. Frontiers in Pharmacology, 14. https://doi.org/10.3389/fphar.2023.1161243

Vancouver

Wu Y, Xu Y, Xu L. Drug therapy for myocarditis induced by immune checkpoint inhibitors. Frontiers in Pharmacology. 2023;14. doi:10.3389/fphar.2023.1161243

BibTeX
@article{Wu2023,
  author = {Wu, Yihao and Xu, Yizhou and Xu, Linhao},
  title = {Drug therapy for myocarditis induced by immune checkpoint inhibitors},
  journal = {Frontiers in Pharmacology},
  year = {2023},
  volume = {14},
  doi = {10.3389/fphar.2023.1161243}
}
Kostenlos starten →